Home / Cancer treatment in China / Breast cancer treatment
Treatment map
Breast Cancer Treatment: Options by Stage, Tumor Type, and Biomarkers
Breast cancer treatment depends on stage, tumor biology, and prior therapy. Teams may use surgery, radiation, hormone therapy, HER2-targeted drugs, chemotherapy, or immunotherapy, but only the tests support a choice. Estrogen receptor, progesterone receptor, and HER2 status are the usual starting tests. Stage and node status change the sequence. Nothing here is a personal plan or a promise of cure.
Applicability: the right combination changes with the pathology report. A hospital name does not replace it.
Stage is not the only switchER, PR, and HER2Not a personal plan
What determines treatment
The National Cancer Institute treats stage as one factor, not the whole plan. The same page lists breast-cancer type, menopause, pregnancy, age, general health, and the person’s preferences. Biomarker testing usually includes estrogen receptor, progesterone receptor, and HER2. Those results sort cancers into groups that do not share one drug list.
Hormone-receptor-positive disease is often treated with hormone therapy. HER2-positive disease can be treated with drugs that target HER2. Triple-negative disease is estrogen-receptor negative, progesterone-receptor negative, and HER2 negative, and it is the setting where NCI says immunotherapy is used. Chemotherapy is more likely when a tumor is high grade, in the lymph nodes, HER2 positive, or triple negative.
Options, without a single sequence
- Surgery removes known disease in the breast. Breast-conserving surgery and mastectomy are both real operations. Mastectomy is not an upgrade by default.
- Radiation often follows surgery to lower the chance of return in the breast or chest wall. It is not automatic after every mastectomy.
- Hormone therapy applies when estrogen and/or progesterone receptors are positive, and NCI also mentions it when receptor status is unknown.
- HER2-targeted drugs apply when HER2 criteria are met, including some HER2-low situations that have their own approvals. HER2-low is not the same label as HER2-positive.
- Chemotherapy may come before or after surgery.
- Immunotherapy, on the NCI patient page, is for triple-negative disease, and not for every triple-negative case.
- A clinical trial can be a reasonable question. A trial is not established care, and screening is not enrollment.
Applicability and limits
This is a routing explanation, not a prescription. A pathology report, imaging, and the treatment history decide the next step. A US approval does not mean a hospital in China offers that drug to an international patient.
There is no universal cure to claim, and no sequence that fits HR-positive, HER2-positive, and triple-negative disease at once. CAR-T is not an established breast-cancer treatment on the NCI breast-drug list used for this page. A registry identifier would be required before a CAR-T offer could even be discussed as a trial.
When a case review may help
A case review is useful when the question is which records a hospital would need, or whether a quoted package ignores subtype. It does not assign a stage, pick a drug, or reserve a bed.
In this cluster
- Breast cancer treatment (this page)
- Treatment by stage
- Latest treatment
- How curable it is
- Immunotherapy
- Treatment in China
Questions people ask
Does every breast cancer need chemotherapy?
No. NCI says chemotherapy is more likely for high-grade tumors, node involvement, HER2-positive disease, and triple-negative disease. The timing still depends on the tumor and the rest of the plan.
Is HER2-low the same as HER2-positive?
No. HER2-positive and HER2-low use different cutoffs. A drug approved for one group is not automatically approved for the other.
Can this page choose my treatment?
No. It explains the factors clinicians use. The pathology report and the treating team choose the plan.
Sources
- NCI, Breast Cancer Treatment by Stage. Retrieved 3 October 2026. The page displayed a 2 December 2025 date.
- NCI, Tests for Breast Cancer Biomarkers. Retrieved 3 October 2026. The page displayed a 2 December 2025 date.
- NCI, Drugs Approved for Breast Cancer. Retrieved 3 October 2026. The page displayed a 23 September 2026 date.
Evidence check: 3 October 2026. US approvals are not proof that a hospital in China stocks the drug or will accept an international patient.
Review a breast cancer case
Stage, receptors, and prior treatment change the question. ParkMega does not diagnose or choose treatment. This prepares a records-ready routing request.